Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”

Article information

Clin Mol Hepatol. 2025;31(1):e90-e92
Publication date (electronic) : 2024 November 11
doi : https://doi.org/10.3350/cmh.2024.0998
1Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China
2Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
Corresponding author : Shao-Lai Zhou Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, 1609 Xie Tu Road, Shanghai 200032, China Tel: +86-21-64041990, Fax: +86-21-64037181, E-mail: zhoushaolai99@sina.com
Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea
Received 2024 November 6; Accepted 2024 November 7.

Dear Editor,

We sincerely appreciated Dr. Sergi Marco and Dr. Chiara Braconi for their valuable and insightful comments [1] regarding our recently published paper titled “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma” [2]. Their comments not only highlighted our contribution in predicting prognosis in intrahepatic cholangiocarcinoma after surgical resection, but also provided profound insights for the shortcoming of our research as well as possible future research directions in this field.

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy with limited treatment [3]. Therefore, new biomarkers for predicting prognosis and the need for new therapies for ICC are of urgent significance. As noted in the editorial, the tumor microenvironment (TME) of ICC, consisting of a variety of cells (cancer cells, stroma cells, immune cells, etc.), has become a focus of study in ICC. In this work [2], based on the tumor stromal composition and immune context, we integrated the stromal-immune signature to predict recurrence-free survival (RFS) and overall survival (OS) in patient of ICC, which is a cost-effective and convenient classifier comparing with complex gene signatures.

In the aspect of tumor stromal composition, we investigated the prognostic value of α-smooth muscle actin (α-SMA)-positive cancer-associated fibroblasts (CAFs) and collagen type 1 fiber deposition. We classified the patients into four groups, dormant (low α-SMA/high collagen), inert (low α-SMA/low collagen), fibrogenic (high α-SMA/high collagen), or fibrolytic (high α-SMA/low collagen), in terms of α-SMA/collagen expression. Four groups of patients showed distinct RFS and OS, reflecting the importance of “stroma-tology” mentioned in the editorial. However, CAFs showed high heterogeneity in their origin, transcriptome, and function. Identified by scRNA-sequencing, human pan-CAF subtypes have been characterized and expanded. Specifically in ICC, CAFs are characterized by expression markers including: α-SMA, collagen type I alpha-1 (COL1A1), vimentin, fibroblast activation protein (FAP), plateletderived growth factor receptor-alpha (PDGFR-α), and platelet-derived growth factor receptor-beta (PDGFR-β) [4]. Yet, more comprehensive research are needed to unveil the next chapter of CAFs regarding their biomarkers and functions. Interestingly, besides our perspective of stromalimmune integration, a publication revealed the clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer throughout single-cell resolution quantitative image analysis combined with spatial transcriptomics [5]. Deciphering the mechanisms by which tumor, immune cells and stromal cells drive cancer aggression is crucial for the advancement of targeted therapies. As Dr. Sergi Marco and Dr. Chiara Braconi emphasized the importance of further research regarding profiling different CAFs, we agreed that we could enhance our analysis more precisely by exploring the diversity of CAFs as they might function and interact uniquely in TME, deepening our understanding of stromal components and offering new insights into therapeutic strategies.

Equally, not only the number, but the diversity of immune cells such as macrophages, neutrophils, T-lymphocytes, did influence the TME and had an impact on patients’ survival. In our work, we stained CD3, CD4, CD8, Foxp3, CD68, CD66b to investigate the infiltration of T helper cells (CD4+ T cells), cytotoxic T cells (CD8+ T cells), regulatory T cells (Tregs) and their associations with stroma and patients’ clinical outcomes. Finally, we sorted out six classes, characterizing a unique stromal-immune signature with decreased median RFS and OS. We found that Group VI, defined by low CD8+ T cell infiltration and high neutrophil infiltration, displayed the worst survival prediction, suggesting the protumoral effect of tumor-associated neutrophils (TANs), which aligned with our previous finding of TANs in hepatocellular carcinoma (HCC) [6]. Interestingly, a recent work indicated the neutrophil divergence across cancers and suggested therapeutic opportunities such as antigenpresenting neutrophil delivery [7]. Thus, the heterogeneous functionality of immune cells may affect TME as well as tumor biology. Concordantly, Dr. Sergi Marco and Dr. Chiara Braconi noted that the heterogeneous functionality of Tlymphocytes and TAMs might contribute to immunosuppressive TME and are worthy of further research. We acknowledged deeper profiling of immune landscape can help accurately sort out valuable subtypes of immune cells and expand our understanding of tumor immunology.

Given that ICC represented high heterogeneity spatiotemporally at macroscopic level and molecular level (including genomics, transcriptomics, proteomics) [8-10]. Previously, our team have explored the ICC microbiome and its association with prognosis [11], KRAS and BRAF variant subtypes with prognosis in patients with ICC [12,13]. With the advancement of ICC therapeutic strategies, the number of ICC patients receiving adjuvant treatment after surgical resection is increasing. Thus, the development of predictive biomarkers of response to adjuvant treatment are of necessity and significance. We are committed to exploring the complicated TME to improve precision and personalized medicine in the future.

Notes

Authors’ contribution

YHY drafted the manuscript. SLZ contributed to the conception, critical revision, and final approval of the manuscript.

Conflicts of Interest

The authors have no conflicts to disclose.

Acknowledgements

This study was jointly supported by the National Natural Science Foundation of China (No. 82372985, No. 82373418, No. 82273247, No. 82173260, No. 82072681, No. 82003082), Shanghai Technical Standard Program (21DZ2201100) and Shanghai Medical Innovation Research Project (22Y11907300).

Abbreviations

CAFs

cancer-associated fibroblasts

COL1A1

collagen type I alpha-1

FAP

fibroblast activation protein

HCC

hepatocellular carcinoma

ICC

intrahepatic cholangiocarcinoma

OS

overall survival

PDGFR-α

platelet-derived growth factor receptor-alpha

PDGFR-β

platelet-derived growth factor receptor-beta

RFS

recurrencefree survival

TANs

tumor-associated neutrophils

TME

tumor microenvironment

Tregs

regulatory T cells

α-SMA

α-smooth muscle actin

References

1. Marco S, Braconi C. Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahe-patic cholangiocarcinoma”. Clin Mol Hepatol 2025;31:323–326.
2. Ye YH, Xin HY, Li JL, Li N, Pan SY, Chen L, et al. Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma. Clin Mol Hepatol 2024;30:914–928.
3. Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2023;73:198–222.
4. Cantallops Vilà P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, Affò S. Heterogeneity, crosstalk, and targeting of cancerassociated fibroblasts in cholangiocarcinoma. Hepatology 2024;79:941–958.
5. Punovuori K, Bertillot F, Miroshnikova YA, Binner MI, Myllymäki SM, Follain G, et al. Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer. Cell 2024;187:7267–7284.e20.
6. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and Tregulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 2016;150:1646–1658.e17.
7. Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 2024;187:1422–1439.e24.
8. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 2017;7:1116–1135.
9. Komuta M. Intrahepatic cholangiocarcinoma: tumour heterogeneity and its clinical relevance. Clin Mol Hepatol 2022;28:396–407.
10. Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 2022;40:70–87.e15.
11. Xin HY, Zou JX, Sun RQ, Hu ZQ, Chen Z, Luo CB, et al. Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma. J Gastroenterol 2024;59:411–423.
12. Zhou SL, Xin HY, Sun RQ, Zhou ZJ, Hu ZQ, Luo CB, et al. Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:59–65.
13. Xin HY, Sun RQ, Zou JX, Wang PC, Wang JY, Ye YH, et al. Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma. JAMA Netw Open 2023;6:e231476.

Article information Continued